Kyowa Kirin is a Japanese biopharmaceutical company specializing in the discovery and development of innovative therapies in nephrology, oncology, immunology, and neurology. The company leverages its proprietary antibody technology platform to develop differentiated biologic medicines, with products marketed in Japan, the United States, and Europe.

For international investors, Kyowa Kirin represents exposure to Japan's innovative pharmaceutical sector with a meaningful global commercial footprint. The company's biologics-focused pipeline and established presence in nephrology — particularly treatments for kidney disease-related conditions — provide a differentiated product profile. As a subsidiary of Kirin Holdings with operational independence, the company benefits from a well-capitalized parent while pursuing its own research and commercial strategy.